The company doesn't seem like it will generate pops in key fundamentals anytime soon.

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

Bio-Rad Laboratories Inc. reported its earnings for the second quarter of 2025, revealing a modest increase in net sales and a stable financial performance. Despite a challenging market environment, ...

One of the two candidates contesting the Irish presidential election has called on the Irish government to prepare for a united Ireland. Catherine Connolly, who has the support of a broad alliance of ...

Unity patches CVE-2025-59489, a high-severity flaw enabling local code execution and data exposure Steam and Valve updated protections; publishers urged to rebuild or patch UnityPlayer.dll in games ...

In context: Since its debut in 2005, Unity has become a fixture of modern game development, powering everything from Cuphead and Hollow Knight to Monument Valley and Genshin Impact. But a newly ...

A vulnerability found in the Unity game engine has led to studio Obsidian Entertainment taking down five of its games, including the premium edition of its 2025 release Avowed. The Unity issue, ...

A code execution vulnerability in the Unity game engine could be exploited to achieve code execution on Android and privilege escalation on Windows. Unity is a cross-platform game engine and ...

Developers who have created their games using Unity have been warned to patch them as soon as possible following the discovery of a security vulnerability in Unity versions 2017.1 and later. In a ...

A security vulnerability found in the Unity engine, which had laid dormant for almost a decade, was recently patched. Games made using the engine also need to be patched, however, so expect a lot of ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...